Johnson & Johnson invests in Delix Therapeutics

Johnson & Johnson is set to lead an $85 million Series C funding round for Delix Therapeutics, a company developing "neuroplastogens," according to Psychedelic Alpha. These compounds are designed to mimic the therapeutic effects of psychedelics without inducing hallucinations. This investment underscores the pharmaceutical industry's growing interest in alternative treatments for mental health disorders.

Delix Therapeutics and Neuroplastogens

Delix Therapeutics has been focusing on creating drugs that retain the therapeutic benefits of psychedelics while eliminating the hallucinogenic effects. One of their leading compounds, DLX-001, an analog of 5-MeO-DMT, showed promising results in a Phase 1B study for major depressive disorder. Participants experienced a 50% reduction in depression symptoms without any serious adverse effects or hallucinogenic experiences.

Johnson & Johnson's Strategic Move

The investment by Johnson & Johnson, known for developing the esketamine nasal spray Spravato, aligns with a broader trend of major pharmaceutical companies acquiring or investing in psychedelic research. Recent acquisitions include Eli Lilly's purchase of AtaiBeckley and Otsuka's acquisition of Transcend Therapeutics. The terms of the Delix deal reportedly include a right of first negotiation following the Phase 2 data of DLX-001.

Why It Matters

The investment in Delix Therapeutics signals a significant shift in the pharmaceutical industry towards exploring non-traditional treatments for mental health. By focusing on neuroplastogens, companies like Johnson & Johnson are betting on the potential of these compounds to provide effective treatments without the side effects associated with traditional psychedelics.

This move also reflects a growing acceptance of psychedelic research within mainstream medicine, potentially leading to new, innovative therapies for conditions like depression and PTSD.

Conclusion

As the interest in psychedelic research grows, investments like Johnson & Johnson's in Delix Therapeutics highlight the potential for these compounds to revolutionize mental health treatment.

Reporting based on The Microdose. Read the original: [link].